Acquisition InterestThe rising values of these transactions highlight the potential for Instil Bio to become an acquisition target of interest, given encouraging data generated to date.
Clinical DevelopmentThe Phase 2 trial of AXN-2510 + chemotherapy in NSCLC is on track to complete enrollment and show initial results, demonstrating progress in clinical development.
Financial OutlookThe 12-month price target for Instil Bio has been increased to $125 from the previous $105, indicating a stronger financial outlook.